Quote Request
Pancreatic Cancer Resistant Cell Model
Chemotherapy resistance is one of the leading causes of pancreatic cancer (PC) therapy failure and eventual death. Effective cell models of drug resistance are critical to building translational bridges between in vitro and in vivo studies to make relevant discoveries. Alfa Cytology uses PC-related expertise and cutting-edge technology to develop highly repeatable and reliable drug-resistant cell models that can be used to gain valuable insights into tumor occurrence, progression, and therapy response.
Overview of Pancreatic Cancer-Resistant Cell Model
Statistics show that more than 90% of cancer deaths are related to drug resistance. Therefore, the persistence of drug resistance remains a major challenge in the development of PC therapies, leading to reduced drug response and disease recurrence. While efforts are underway to identify resistance mechanisms and develop new drugs and therapeutics to overcome them, the lack of physiologically relevant drug-resistant cancer model systems remains a major challenge.
Fig. 1 Different mechanisms of drug resistance in pancreatic cancer. (Quiñonero F., et al., 2019)
Developing drug-resistant cell lines is critical to studying resistance mechanisms and identifying alternative treatment pathways. There are two forms of resistance to cancer, which are intrinsic resistance and acquired resistance.
| Types | Description |
|---|---|
| Intrinsic resistance | Intrinsic resistance is present before treatment, giving cancer cells an inherent ability to survive in the presence of the drug. Poor initial response to therapy indicates possible intrinsic resistance. |
| Acquired resistance | Acquired resistance occurs after an initial positive response to treatment. In this condition, cancer cells gradually acquire specific genetic abnormalities or protein alterations that eventually lead to non-response to treatment and cancer recurrence. |
Our Services
The complexity of cancer genomics and tumor biology allows pancreatic cancer to develop new resistance mechanisms to existing or emerging cancer therapies. New cancer therapies are evaluated through expensive low-throughput animal studies and clinical trials. Therefore, there is an urgent need for complex, three-component, and multi-component in vitro cancer models that simulate the plasticity of tumor cells and tumor microenvironments.
Cell models are key for understanding resistance mechanisms and developing novel therapies. Alfa Cytology is working to develop state-of-the-art models of resistant pancreatic cancer cells to improve traditional drug-resistant models.
| Models | Descriptions | Applications |
|---|---|---|
 Drug-Selected Resistant Cell Lines |
This model works by exposing pancreatic cancer cells to a specific drug or therapy that increases in concentration over time and eventually creates a resistant cell line. |
|
 Genetically Engineered Resistant Cell Lines |
Genetically engineered drug-resistant cell lines are generated by introducing specific genetic changes into cancer cells to mimic the genetic changes observed in drug-resistant tumors. |
|
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
Each type of cell model has its own advantages and limitations, and using a combination of several models can more comprehensively study drug resistance in pancreatic cancer and develop new treatments. If you are interested in our services, please contact us for more details. You can contact our staff directly and receive professional, reliable, and fast feedback.
Reference
- Quiñonero F, et al. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biol Med. 2019;16(4):688-699. doi:10.20892/j.issn.2095-3941.2019.0252
